title: Large differences in blood measures, tissue weights, and focal areas of damage 1 year after postseizure treatment with acepromazine or ketamine.
abstract: Approximately 1 year after rats were seized as young adults with lithium (3 mEq/kg) and pilocarpine (30 mg/kg) and given acepromazine or ketamine, 18 blood measures, wet tissue weights, and detailed damage scores for 107 brain structures were completed. Compared with normal and ketamine-treated rats, acepromazine-treated seized rats (total n=54) had lighter pancreata and spleens and elevated aspartate aminotransferase and alanine aminotransferase blood levels. Even though average damage did not differ, the mosaic of brain damage completely discriminated the two seized groups. Differential effects of postseizure treatment on functions of the thyroid, pancreas, and spleen were indicated. Ketamine-treated seized rats were healthier than acepromazine-treated seized rats or normal rats. This experiment demonstrates the importance of whole-organism assessment and that the single administration of a specific drug after onset of status epilepticus can produce marked differences in the evolution of brain damage and its influence on specific organs for the rest of the animal's life.
authors.affiliation: Department of Biology, Laurentian University, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.
authors.forename: Katherine R
authors.initials: KR
authors.lastname: George
authors.forename: Timothy
authors.initials: T
authors.lastname: Rico
authors.forename: Linda S
authors.initials: LS
authors.lastname: St-Pierre
authors.forename: Mathieu J
authors.initials: MJ
authors.lastname: Dupont
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Dupont
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Blomme
authors.forename: Angelo
authors.initials: A
authors.lastname: Mazzuchin
authors.forename: Lee S
authors.initials: LS
authors.lastname: Stewart
authors.forename: Michael A
authors.initials: MA
authors.lastname: Persinger
mesh_terms: D000075:Acepromazine / Q000494:pharmacology / Q000627:therapeutic use*; D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D007649:Ketamine / Q000494:pharmacology / Q000627:therapeutic use*; D018021:Lithium Chloride; D008137:Longitudinal Studies; D008297:Male; D009460:Neurologic Examination; D009929:Organ Size / Q000187:drug effects*; D010862:Pilocarpine; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology*; D013223:Statistics as Topic; D013961:Thyroid Gland / Q000187:drug effects / Q000473:pathology
chemical_list: D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D010862:Pilocarpine; D000075:Acepromazine; D007649:Ketamine; D018021:Lithium Chloride